This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Kedrion Biopharma Inc.
Kedrion Biopharma Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States and operates extensively across North America and Europe. Founded in 2001, the company has established itself as a leader in the development and production of high-quality plasma-derived therapies, catering to patients with rare and chronic conditions. Kedrion's core offerings include immunoglobulins, clotting factors, and albumin, all distinguished by their rigorous quality standards and commitment to patient safety. With a strong focus on innovation and sustainability, Kedrion has achieved significant milestones, including strategic partnerships and expansions that enhance its market position. The company is dedicated to improving patient outcomes and continues to make strides in the biopharmaceutical landscape.
DitchCarbon Score
How does Kedrion Biopharma Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Kedrion Biopharma Inc.'s score of 41 is higher than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Kedrion Biopharma Inc.'s reported carbon emissions
In 2024, Kedrion Biopharma Inc. reported total carbon emissions of approximately 26,122,000 kg CO2e for Scope 1 and about 54,381,000 kg CO2e for Scope 2 (market-based). In 2023, the company’s emissions were approximately 27,731,000 kg CO2e for Scope 1 and about 51,432,000 kg CO2e for Scope 2 (market-based). This indicates a reduction in Scope 1 emissions from 2023 to 2024. Kedrion's emissions data shows a consistent commitment to monitoring and reducing its carbon footprint. The company has set ambitious climate commitments through its Net Zero Program, which aims to implement strategies for reducing emissions in both Scope 1 and Scope 2 by 2025. This initiative is part of their broader Sustainability Plan, which began in 2023. The emissions data for Kedrion Biopharma Inc. is cascaded from its parent company, Kedrion Holding Spa, reflecting a corporate family relationship. The company does not currently report Scope 3 emissions, which are often significant in the biopharma industry. Overall, Kedrion Biopharma Inc. is actively working towards its climate commitments, with a focus on achieving net-zero emissions in the near term.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 32,736,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 21,143,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Kedrion Biopharma Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
